Authors: Kawasaki, Eiji; Eguchi, Katsumi

Source: Current Pharmacogenomics, Volume 3, Number 3, September 2005 , pp. 191-199(9)

Publisher: Bentham Science Publishers

Abstract:

Type 1 diabetes is an organ-specific autoimmune disease characterized by T-cell mediated destruction of pancreatic -cells. A variety of environmental and genetic factors are involved in the development of the disease. The human leukocyte antigen (HLA) class II genes (termed IDDM1) are the major genes associated with susceptibility to type 1 diabetes. The highest risk for type 1 diabetes in Caucasian population is associated with individuals expressing both DRB1*0301-DQB1*0201 and DRB1*0401-DQB1*0302. However, HLA-DRB1*0405-DQB1*0401, HLADRB1* 0901-DQB1*0303 and HLA-DRB1*0802-DQB1*0302 are three major susceptible haplotypes in Japanese patients with type 1 diabetes. In contrast, the most protective HLA DR-DQ haplotype, DRB1*1501-DQB1*0602, is universal. Other genetic factors reported in type 1 diabetes include the polymorphisms in insulin gene (IDDM2), CTLA4 gene (IDDM12), PTPN22 gene, IL-18 gene, TNF- gene, Neuro D/BETA 2 gene, Vitamin D receptor gene, and SDF-1 gene. Within the last decade, a number of immunological and environmental manipulations in animal models of type 1 diabetes, NOD mouse and BB rat, have been reported. In humans, two major trials have been conducted to try to prevent type 1 diabetes with administration of insulin and nicotinamide (DPT-1 and ENDIT). To date, no treatment has been shown to prevent human type 1 diabetes. However, if a safe and effective therapy is identified, one should consider the use of agent for high risk individuals to prevent diabetes, as well as for the patients with type 1 diabetes in adults who are often diagnosed as having type 2 diabetes to preserve residual -cell function based on the findings of both immunogenetic and pharmacogenetic testing to predict responders from non-responders.

Keywords: type diabetes; autoantibodies; genetics; heterogeneity; immunology; autoantigen

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1570160054864030

Affiliations: 1: Department of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University Hospital of Medicine and Dentistry, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.

Publication date: 2005-09-01

More about this publication?

• Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.
  
  The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology ,  Genetics
• By this author: Kawasaki, Eiji ;  Eguchi, Katsumi

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers